ClinicalTrials.gg
Active, not recruitingNCT03528694POTOMACUpdated Jul 7, 2026

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

A Phase 3 interventional study of Durvalumab (MEDI4736) and Bacillus Calmette-Guerin (BCG) in Non-muscle-invasive Bladder Cancer, sponsored by AstraZeneca. Active, not recruiting at 120 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,018
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Japan — 5 open to participants now, 10 under way, 7 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Japan.

Enrollment
2nd of 12
1,018 · median 254
Started
2018
the only one that year
Phase 3
7 of 12
3 open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
AstraZeneca

Among the 12 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Japan, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 7 in phase 3, and was the 2nd registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

5 of the 12 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer

Read the detailed description

Patients will be randomized in a 1:1:1 ratio to receive treatment with Durvalumab + BCG combination therapies, or Standard of Care (SoC) therapy.

03

Conditions studied

  • Non-muscle-invasive Bladder Cancer

Keywords

  • Durvalumab
  • BCG
  • MEDI4736
  • NMIBC
  • PD-L1
  • DFS
  • OS
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: For inclusion in the study, patients should fulfill the following criteria:

  • Aged at least 18 years
  • BCG-naïve (patients who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before study entry are eligible)
  • Local histological confirmation (based on pathology report) of high-risk transitional cell carcinoma of the urothelium of the urinary bladder confined to the mucosa or submucosa. A high risk tumor is defined as one of the following

    • T1 tumor
    • High grade/ G3 tumor
    • CIS
    • Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point)
  • Complete resection of all Ta/T1 papillary disease prior to randomization, with the TURBT removing high-risk NMIBC performed not more than 4 months before randomization in the study. Patients with residual CIS after TURBT are eligible
  • No prior radiotherapy for bladder cancer
  • No prior exposure to immune-mediated therapy of cancer including, but not limited to, other anti , anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 antibodies. Patients who have been treated with anticancer vaccines will be excluded

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  • Evidence of muscle-invasive, locally advanced, , and/or extra vesical bladder cancer (ie, T2, T3, T4, and / or stage IV)
  • Concurrent extravesical (ie, urethra, ureter, or renal pelvis), non-muscle-invasive transitional cell carcinoma of the urothelium
  • Previous product (IP) assignment in the present study
  • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for noncancer related conditions (eg, hormone replacement therapy) is acceptable. Chemotherapy for previous instances of NMIBC is acceptable.
  • Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician
    • Patients with celiac disease controlled by diet alone
  • History of another primary except for

    • Malignancy treated with curative intent and with no known active disease ≥ 2 years before the first dose of IP and of low potential risk for recurrence during the study period
    • Adequately treated nonmelanoma skin cancer or lentigo maligna withoutevidence of disease
    • Adequately treated CIS without evidence of disease
    • Prostate cancer (tumor/node/metastasis stage) of stage ≤ T2cN0M0 without biochemical recurrence or progression that in the opinion of the Investigator does not require active intervention
  • Current or prior use of medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical , or local steroid injections (eg, intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    • Steroids as premedication for reactions (eg, computed tomography [CT] scan premedication)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,018 participants (actual)

Study arms

  • Experimental
    Durvalumab plus BCG (induction + maintenance)

    Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy

    Biological: Durvalumab (MEDI4736) · Biological: Bacillus Calmette-Guerin (BCG)

  • Experimental
    Durvalumab plus BCG (induction only)

    Durvalumab (MEDI4736) plus Bacillus Calmette-Guerrin (BCG) combination therapy

    Biological: Durvalumab (MEDI4736) · Biological: Bacillus Calmette-Guerin (BCG)

  • Active comparator
    BCG treatment (Standard of care therapy)

    Bacillus Calmette-Guerrin (BCG) standard of care treatment

    Biological: Bacillus Calmette-Guerin (BCG)

Interventions

06

What researchers measure

Primary outcomes

  1. The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC

    Disease-free survival using Investigator disease assessments.

    Time frame: Up to 4 years

Secondary outcomes

  1. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of DFS 24 months

    Proportion of patients alive and disease free at 24 months using Investigator disease assessments. DFS24 is defined as the proportion of patients alive and disease-free at 24 months after randomization, per Investigator disease assessment.

    Time frame: Up to 4 years

  2. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of OS5

    Overall survival at 5 years. Overall survival (OS) is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization +1). Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive

    Time frame: Up to 7 years

  3. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of any disease-free survival

    Any disease-free survival using Investigator disease assessments. Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments.

    Time frame: Up to 7 years

  4. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of Time to MIBC and/or Metastatic Disease

    Time to MIBC and/or metastatic disease using Investigator disease assessments. Time to MIBC and/or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and/or metastatic disease as assessed by Investigator. Time to MIBC and/or metastatic disease does not include deaths. If patients died without MIBC and/or metastatic disease, they will be censored at the time of death. All other censoring rules per DFS analysis will be applied including censoring patients with an event after 2 missed visits and patients with no evaluable disease assessments or no baseline data.

    Time frame: Up to 4 years

  5. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone with respect to time to cystectomy

    Time to cystectomy using Investigator disease assessments. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as reported by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Patients who have not had a cystectomy at the time of analysis will be censored at the last recorded date on which the patient was known to be alive. No other censoring rules per the DFS analysis will be applied.

    Time frame: Up to 4 years

  6. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to BCG (induction and maintenance) alone in terms of time to development of upper tract urothelial carcinoma

    Time to development of upper tract urothelial carcinoma using Investigator disease assessments. Time to development of upper tract urothelial carcinoma (TTUTUC) is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator using CT urography or ureteroscopy (less common). TTUTUC does not include deaths. Patients who died without upper tract urothelial carcinoma will be censored at the time of death. Other censoring rules per DFS analysis will be applied, including censoring patients with no baseline data but excluding censoring patients with an event after 2 missed visits as evaluation of the upper urinary tract is not part of regular disease assessment and is performed as clinically indicated.

    Time frame: Up to 7 years

  7. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of Disease-free survival

    Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments.

    Time frame: Up to 7 years

  8. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of patients alive and disease free at 24 months

    Proportion of patients alive and disease free at 24 months using Investigator disease assessments. DFS24 is defined as the proportion of patients alive and disease-free at 24 months after randomization, per Investigator disease assessment

    Time frame: Up to 24 months

  9. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of OS5

    Overall survival at 5 years. Overall survival (OS) is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization +1).

    Time frame: up to 5 years

  10. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of any disease-free survival

    Any disease-free survival using Investigator disease assessments. Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments.

    Time frame: Up to 7 years

  11. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of Time to MIBC and/or metastatic disease

    Time to MIBC and/or metastatic disease using Investigator disease assessments. Time to MIBC and/or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and/or metastatic disease as assessed by Investigator. Time to MIBC and/or metastatic disease does not include deaths. If patients died without MIBC and/or metastatic disease, they will be censored at the time of death. All other censoring rules per DFS analysis will be applied including censoring patients with an event after 2 missed visits and patients with no evaluable disease assessments or no baseline data.

    Time frame: Up to 7 years

  12. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone in terms of time to cystectomy

    Time to cystectomy using Investigator disease assessments. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as reported by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Patients who have not had a cystectomy at the time of analysis will be censored at the last recorded date on which the patient was known to be alive. No other censoring rules per the DFS analysis will be applied.

    Time frame: Up to 7 years

  13. To assess the efficacy of durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone time to development of upper tract urothelial carcinoma

    Time to development of upper tract urothelial carcinoma using Investigator disease assessments. Time to development of upper tract urothelial carcinoma (TTUTUC) is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator using CT urography or ureteroscopy (less common). TTUTUC does not include deaths. Patients who died without upper tract urothelial carcinoma will be censored at the time of death. Other censoring rules per DFS analysis will be applied, including censoring patients with no baseline data but excluding censoring patients with an event after 2 missed visits as evaluation of the upper urinary tract is not part of regular disease assessment and is performed as clinically indicated.

    Time frame: Up to 7 years

  14. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Disease-free survival

    Disease-free survival using Investigator disease assessments.Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments.

    Time frame: Up to 4 years

  15. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Proportion of patients alive and disease free at 24 months

    Proportion of patients alive and disease free at 24 months using Investigator disease assessments. DFS24 is defined as the proportion of patients alive and disease-free at 24 months after randomization, per Investigator disease assessment.

    Time frame: Up to 24 months

  16. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Overall survival at 5 years

    Overall survival (OS) is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e. date of death or censoring - date of randomization +1). The proportion of patients alive at 5 years (OS5)

    Time frame: Up to 7 years

  17. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of any disease-free survival

    Any disease-free survival using Investigator disease assessments. Any disease-free survival (aDFS) is defined similarly as DFS, except that aDFS includes recurrence of low/medium risk NMIBC. This will be based on Investigator disease assessments.

    Time frame: up to 5 years

  18. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of time to MIBC and/or metastatic disease

    Time to MIBC and/or metastatic disease using Investigator disease assessments. Time to MIBC and/or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and/or metastatic disease as assessed by Investigator. Time to MIBC and/or metastatic disease does not include deaths. If patients died without MIBC and/or metastatic disease, they will be censored at the time of death. All other censoring rules per DFS analysis will be applied including censoring patients with an event after 2 missed visits and patients with no evaluable disease assessments or no baseline data.

    Time frame: up to 5 yeas

  19. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of time to cystectomy

    Time to cystectomy using Investigator disease assessments. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as reported by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Patients who have not had a cystectomy at the time of analysis will be censored at the last recorded date on which the patient was known to be alive. No other censoring rules per the DFS analysis will be applied.

    Time frame: up to 5 years

  20. To assess the efficacy of durvalumab + BCG (induction and maintenance) combination therapy compared to durvalumab + BCG (induction only) in terms of Time to development of upper tract urothelial carcinoma

    Time to development of upper tract urothelial carcinoma using Investigator disease assessments. Time to development of upper tract urothelial carcinoma (TTUTUC) is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator using CT urography or ureteroscopy (less common). TTUTUC does not include deaths. Patients who died without upper tract urothelial carcinoma will be censored at the time of death. Other censoring rules per DFS analysis will be applied, including censoring patients with no baseline data but excluding censoring patients with an event after 2 missed visits as evaluation of the upper urinary tract is not part of regular disease assessment and is performed as clinically indicated.

    Time frame: up to 5 years

  21. Complete response rate (CRR) at 6 months using Investigator disease assessments

    To assess the efficacy of durvalumab + BCG combination therapy compared to BCG (induction and maintenance) for patients with CIS prior to study entry or at baseline cystoscopy.

    Time frame: up to 6 months

  22. EORTC QLQ-C30 and EORTC QLQ-NMIBC24

    To assess disease-related symptoms and HRQoL in patients with NMIBC treated with durvalumab + BCG (induction and maintenance) combination therapy and durvalumab + BCG (induction only) combination therapy compared to BCG (induction and maintenance) alone and compared to each other using the EORTC QLQ-C30 questionnaire and the EORTC QLQ-NMIBC24 questionnaire

    Time frame: up to 5 years

  23. PRO version of the CTCAE with approximately 19 items (PRO-CTCAE) symptoms in countries where language is available

    To assess patient-reported treatment tolerability directly using specific PRO-CTCAE symptoms

    Time frame: up to 5 years

  24. PK serum concentration of durvalumab

    To assess the PK of durvalumab when used in combination with BCG treatment

    Time frame: up to 5 years

  25. Presence of ADAs for durvalumab

    To investigate the immunogenicity of durvalumab when used in combination with BCG treatment

    Time frame: up to 5 years

07

Study locations

120 sites
  • Research Site
    Auchenflower, 4066, Australia
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Brisbane, 4122, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Orange, 2800, Australia
  • Research Site
    Parkville, 3000, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Kingston, Ontario K7L 3J7, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Amiens, 80054, France
  • Research Site
    Angers, 49033, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Lyon, 69437, France
  • Research Site
    Marseille, 13003, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Strasbourg, 67098, France
  • Research Site
    Suresnes, 92151, France
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Cologne, 50968, Germany
  • Research Site
    Duisburg, 47169, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    Mettmann, 40822, Germany
  • Research Site
    Mühlheim An Der Ruhr, 45468, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Nürtingen, 72622, Germany
  • Research Site
    Wesel, 46483, Germany
  • Research Site
    Würselen, 52146, Germany
  • Research Site
    Zirndorf, 90513, Germany
  • Research Site
    Bunkyō City, 113-8603, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Hirosaki-shi, 036-8563, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Kita-gun, 761-0793, Japan
  • Research Site
    Koshigaya-shi, 343-8555, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Matsuyama, 791-0280, Japan
  • Research Site
    Miyazaki, 889-1692, Japan
  • Research Site
    Nagasaki, 852-8501, Japan
  • Research Site
    Nagoya, 467-0001, Japan
  • Research Site
    Okayama, 700-8558, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Osaka, 545-8586, Japan
  • Research Site
    Osakasayama-shi, 589-8511, Japan
  • Research Site
    Sapporo, 060-8543, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
  • Research Site
    Toyama, 930-0194, Japan
  • Research Site
    Tsukuba, 305-8576, Japan
  • Research Site
    Yokohama, 232-0024, Japan
  • Research Site
    Amsterdam, 1081 HV, Netherlands
  • Research Site
    Breda, 4818 CK, Netherlands
  • Research Site
    Utrecht, 3543 AZ, Netherlands
  • Research Site
    Bialystok, 15-950, Poland
  • Research Site
    Gdansk, 80-952, Poland
  • Research Site
    Grudziądz, 86-300, Poland
  • Research Site
    Koszalin, 75-581, Poland
  • Research Site
    Piotrkow Trybunalski, 97-300, Poland
  • Research Site
    Poznan, 61-731, Poland
  • Research Site
    Warsaw, 02-005, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Wroclaw, 50-556, Poland
  • Research Site
    Wroclaw, 53-413, Poland
  • Research Site
    Ivanovo, 153040, Russia
  • Research Site
    Krasnoyarsk, 660133, Russia
  • Research Site
    Moscow, 105077, Russia
  • Research Site
    Moscow, 115280, Russia
  • Research Site
    Moscow, 125367, Russia
  • Research Site
    Nizhny Novgorod, 603074, Russia
  • Research Site
    Obninsk, 249036, Russia
  • Research Site
    Omsk, 644013, Russia
  • Research Site
    Saint Petersburg, 191014, Russia
  • Research Site
    Saint Petersburg, 194017, Russia
  • Research Site
    Saint Petersburg, 194044, Russia
  • Research Site
    Saint Petersburg, 194354, Russia
  • Research Site
    Saint Petersburg, 195271, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Vologda, 160012, Russia
  • Research Site
    Yaroslavl, 150054, Russia
  • Research Site
    Badajoz, 06008, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 08208, Spain
  • Research Site
    Barcelona, 8003, Spain
  • Research Site
    Elche(Alicante), 03202, Spain
  • Research Site
    Madrid, 08035, Spain

Showing the first 100 of 120 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • De Santis M, Palou Redorta J, Nishiyama H, Krawczynski M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, Puente J, Hellmis E, Powles T, Radziszewski P, Gust KM, Vasey P, Bigot P, Fradet Y, Hunting J, Armstrong J, Boulos S, Hois S, Shore ND; POTOMAC Investigators. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet. 2025 Nov 8;406(10516):2221-2234. doi: 10.1016/S0140-6736(25)01897-5. Epub 2025 Oct 17. PubMed 41115436 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Apr 2025, 82 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
May 18, 2018
StartActual
May 14, 2018
Primary completionActual
Apr 3, 2025
CompletionEst.
Oct 3, 2028
Results delay requested
Apr 3, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03528694
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 18, 2018
Start date
May 14, 2018
Primary completion
Apr 3, 2025
Completion
Oct 3, 2028 (estimated)
Last update
Jul 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion